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Abstract
Background: Long-acting bronchodilator monotherapy (long-acting β2-agonist [LABA] or long-acting muscarinic
antagonist [LAMA]) is extensively used for treatment of patients with chronic obstructive pulmonary disease (COPD)
with mild-to-moderate airflow limitation. However, a substantial number of patients remain symptomatic despite
treatment with a single bronchodilator, necessitating a change in therapy.
Methods: This 12-week, randomized, multicenter, open-label, phase IV study aims to show that the once-daily
indacaterol/glycopyrronium (IND/GLY) 110/50 μg fixed-dose LABA/LAMA combination results in an improved
lung function in symptomatic patients with mild-to-moderate COPD who switch from once-daily tiotropium
18 μg. The study aims to enroll a total of 404 symptomatic patients in Korea with mild-to-moderate COPD who
received tiotropium for at least 12 weeks prior to the study initiation. The primary objective of this study is to
demonstrate the superiority of IND/GLY over tiotropium in terms of trough forced expiratory volume in 1 second
(FEV1) following 12 weeks of treatment. Secondary endpoints include the pre-dose trough FEV1 after 4 weeks
of treatment, transition dyspnea index (TDI) total score, COPD assessment test (CAT) total score, and rescue
medication use following the 12-week treatment, and safety assessment over the 12-week treatment.
Discussion: This study intends to establish the use of LABA/LAMA combination therapy in symptomatic patients
with mild-to-moderate COPD by demonstrating the superiority of IND/GLY over tiotropium monotherapy.
Trial registration: ClinicalTrials.gov, NCT02566031. Registered on 10 August 2015.
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Background
Chronic obstructive pulmonary disease (COPD) is a pro-
gressive respiratory disorder characterized by persistent
airflow limitation. COPD is a highly prevalent disorder
affecting around 210 million adults worldwide and
accounting for nearly 3 million deaths per year [1, 2].
Among Korean adults aged ≥40 years, COPD prevalence
in 2008, determined using spirometry was 13.4% [3]. In
the Korean population, according to the Korea National
Health and Nutrition Examination Survey, this corre-
sponds to an estimated prevalence of 3.2 million cases [3].
Current Global Strategy for the Diagnosis, Manage-
ment and Prevention of COPD (GOLD) strategy, defines
severity of COPD in patients based on the assessment of
lung function, symptoms, and exacerbation risk and
classifies patients into four groups, A, B, C, or D [4]. Pa-
tients in groups A and C have fewer symptoms, and
those in groups B and D have more symptoms. Patients
with COPD, particularly with mild-to-moderate airflow
limitation (trough forced expiratory volume in 1 second
[FEV1] ≥ 50% of the predicted value), with <2 exacerba-
tions in the previous year not requiring hospitalization
for exacerbation, and with COPD assessment test (CAT)
score ≥10 or modified Medical Research Council
(mMRC) grade ≥2 are classified in GOLD group B, i.e.,
patients with low risk and more symptoms [4, 5].
GOLD strategy recommends the use of long-acting
mono-bronchodilators, including a long-acting β2-agon-
ist (LABA) or a long-acting muscarinic antagonist
(LAMA), as the first-line therapy for the treatment of
GOLD group B patients [6]. However, a significant pro-
portion of patients receiving long-acting bronchodilator
monotherapy continue to experience symptoms and
poor quality of life [7]. Hence, the over-prescription of
inhaled corticosteroids (ICS) (in combination with a
LABA or a LAMA) has been frequently reported in
group B patients, leading to increased risk of pneumonia
and other side effects [8]. Recently, combination of
bronchodilators such as a LABA and a LAMA that tar-
get different bronchodilation pathways has been shown
to enhance bronchodilation in symptomatic patients [9].
The evidence from prospective clinical studies also indi-
cates greater improvement in lung function with LABA/
LAMA combination therapy compared with increasing
the dose of a single bronchodilator in patients with
moderate-to-severe COPD [10].
The once-daily fixed-dose combination of indacaterol
(IND, a LABA)/glycopyrronium (GLY, a LAMA) 110/50
μg combines these two bronchodilators in a single
inhaler and is approved for maintenance treatment of
patients with moderate-to-severe COPD. IND/GLY was
first marketed in Europe in 2013 and has since been
marketed in more than 90 countries globally, including
in Korea since May 2014.
Rationale
Treatment with a single bronchodilator such as a LAMA
is recommended for group B patients by the GOLD strat-
egy. This study aims to evaluate the effect of the alterna-
tive treatment with a LABA/LAMA combination (IND/
GLY 110/50 μg) in GOLD group B (FEV1 ≥ 50% of the
predicted normal value and CAT ≥10) patients who re-
main symptomatic despite maintenance treatment with a
LAMA. As tiotropium is currently the most widely used
LAMA in COPD treatment in Korea, this has been se-
lected as the comparator in this study.
This study aims to provide evidence in addition to the
existing data to demonstrate the superiority of once-daily
IND/GLY 110/50 μg over once-daily tiotropium18 μg in
improving lung function over once-daily tiotropium18 μg
in symptomatic patients with mild-to-moderate COPD.
Furthermore, this study aims to explore the effects of
IND/GLY versus tiotropium on symptom burden, breath-
lessness, and use of rescue medication in these patients.
Methods
Study design
This is a 12-week, randomized, multicenter, open-label,
parallel-group, phase IV study. At an initial pre-screening
visit (visit 0), a written informed consent will be obtained,
followed by assessing the inclusion/exclusion criteria and
baseline COPD medication and demographics data. Follow-
ing a 3-week screening period, at visit 1, eligible patients
will be randomized in a 1:1 ratio to receive either once-
daily IND/GLY 110/50 μg delivered via the Breezhaler® de-
vice (Novartis Pharma AG, Basel, Switzerland) or once-
daily tiotropium 18 μg delivered via the HandiHaler® device
(Boehringer Ingelheim, Ingelheim, Germany) during a 12-
week treatment period (Fig. 1). Spirometry measurements
assessing the post-bronchodilator FEV1, along with the
baseline dyspnea index (BDI), mMRC and CAT assess-
ments will also be performed at visit 1.During the study, pa-
tients will be permitted to use salbutamol/albuterol (short-
acting bronchodilator) as a rescue medication, as needed.
The schedule of visits and measurements is given in Fig. 2.
Ethical conduct of the study and informed consent
This study will be conducted in 20 centers, comprising
of general hospitals. The study will be conducted in ac-
cordance with the Declaration of Helsinki and Good
Clinical Practice guidelines and has been approved by
the institutional review boards and ethics committees at
participating centers (list included in Additional file 1).
Written informed consent will be obtained from every
participant in the study.
Patients
The first patient’s first visit for the study took place in
January 2016 and the recruitment is expected to conclude
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by the end of 2017. In line with the inclusion/exclusion
criteria, this study aims to enroll a total of 404 symptom-
atic patients with mild-to-moderate COPD in Korea who
would have received tiotropium for at least 12 weeks prior
to the study initiation and would be given either IND/
GLY or tiotropium for 12 weeks.
Inclusion criteria
Male or female patients to be enrolled in the study should
meet the following inclusion criteria: age ≥40 years; con-
firmed diagnosis of COPD with mild or moderate airflow
limitation, post-bronchodilator FEV1 ≥ 50% of the pre-
dicted value, and FEV1/forced vital capacity (FVC) ratio
<0.7; CAT score ≥10 at screening along with a history of
<2 exacerbations; and no hospitalization for exacerbation
in the previous 12 months. Patients must be current or
ex-smokers with a smoking history of ≥10 pack-years and
must be on tiotropium monotherapy for at least 12 weeks
before the study initiation.
Exclusion criteria
Key exclusion criteria include a history of treatment with
any ICS in 12 weeks prior to the study initiation; a history
or current diagnosis of cardiac arrhythmias; or a history of
familial long QT syndrome or type I or uncontrolled type
II diabetes or narrow-angle glaucoma. Patients requiring
long-term oxygen therapy prescribed for >12 hours per
day or experiencing COPD exacerbation during the 12-
week screening period that requires hospitalization or
with a history of respiratory tract infection within 4
weeks prior to the screening or who develop a respiratory
tract infection during the screening or with a history of
any concomitant pulmonary disease or with a history or
current diagnosis of asthma will also be excluded.
Randomization
All eligible patients will be randomized (1:1) using the
interactive randomized technology (IRT) to one of the
treatment arms. The IRT will assign a randomization
number to the patient, which will be used to link the pa-
tient to a treatment arm and will specify a unique medi-
cation number for the first package of study drug to be
dispensed to the patient.
To ensure that the treatment assignment is unbiased and
concealed from both patients and investigators the patient
randomization list will be produced by the IRT provider
using a validated system that automates the random assign-
ment of patient numbers to randomization numbers. These
randomization numbers are linked to the different treatment
arms, which in turn are linked to medication numbers.
Objectives
The primary objective of the study is to demonstrate the
superiority of IND/GLY over tiotropium monotherapy in
terms of trough FEV1 (defined as the mean of the pre-
dose 45 and 15 minutes FEV1 values), following 12 weeks
of treatment in patients with mild-to-moderate symptom-
atic COPD. Secondary objectives are to evaluate pre-dose
trough FEV1 after 4 weeks of treatment, transition dys-
pnea index (TDI) total score, total CAT score, and rescue
medication use following the 12-week treatment. Safety
and tolerability will also be assessed over the 12-week
treatment. Safety assessment will include monitoring of all
the adverse events (AEs) and serious adverse events
(SAEs) (regardless of causality); measuring vital signs, in-
cluding pulse rate and blood pressure; and performing
complete physical examinations, clinical laboratory tests,
and electrocardiograms. The occurrence of AEs will be
sought by non-directive questioning of the patient at each
visit during the study or may also be detected by patient
volunteering during or between visits or through physical
examination, laboratory test, or other assessments.
Exploratory objectives will assess patient preference and
satisfaction with IND/GLY in the group of patients receiv-
ing IND/GLY, after the patients have been treated with
both regimens. Other exploratory outcome measures will
comprise of mMRC dyspnea scale scores after 4 and 12
weeks of the treatment and the correlation between pa-
tients’ mMRC and CAT scores.
Statistical analysis
The efficacy analysis will be performed on the full ana-
lysis set (FAS), whereas the per protocol set (PPS) will
be used for supportive analysis of the primary variable.
The FAS will comprise all randomized patients who re-
ceive at least one dose of study treatment and will have
at least one evaluable post-baseline assessment. The PPS
will include all patients in the FAS without any major
protocol deviations. All safety analyses will be performed
COPD, chronic obstructive pulmonary disease; 
GLY, glycopyrronium; IND, indacaterol
Fig. 1 Study design
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on the safety set comprising of all patients who receive
at least one dose of the study treatment.
An analysis of covariance (ANCOVA) model will be
used for the primary analysis with treatment, smoking
status as fixed effects, baseline trough FEV1 as a covariate
and center as a random effect. The superiority of IND/
GLY to tiotropium will be demonstrated if the p value is
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Fig. 2 Schedule of enrolment, interventions and assessments
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to the right of (higher than) 0 mL. In addition, the primary
analysis will be repeated for the PPS as a supportive ana-
lysis. The missing FEV1 values will be imputed by the last
observation carried forward (LOCF) method.
Moreover, trough FEV1 at week 4 will be analyzed using
an ANCOVA model similar to the primary analysis, with
visit and treatment by visit interactions as additional fixed
effects. The TDI total score at week 12 will be analyzed
using the same ANCOVA model with the baseline dys-
pnea index (BDI) focal score as the baseline covariate. The
proportion of patients with a clinically important improve-
ment of at least 1 in the TDI focal score will be analyzed
using logistic regression. The CAT score after 12 weeks of
treatment will be summarized based on treatment and an-
alyzed using similar ANCOVA model, with the baseline
covariate replaced by baseline CAT score.
Sample size calculation
This study aims to randomize 182 patients in each treat-
ment arm (IND/GLY and tiotropium) to demonstrate the
superiority of IND/GLY over tiotropium in terms of pre-
dose trough FEV1 following 12 weeks of treatment at 5%
level of significance with 80% power on a two-sided test.
This is based on the assumptions that the estimated treat-
ment difference between IND/GLY and tiotropium is 80
mL and corresponding standard deviation is 271 mL [10].
Therefore, considering a dropout rate of 11%, approxi-
mately 404 patients are to be enrolled in the study.
Discussion
Once-daily fixed-dose combination IND/GLY 110/50
μg has been shown to significantly improve lung
function and patient-reported outcomes (including
dyspnea and health status) versus placebo [11, 12].
In addition, IND/GLY showed significant improve-
ments in bronchodilation when compared with its
monocomponents and tiotropium in moderate-to-
severe COPD patients [11, 13]. These improvements
were rapid in onset and sustained throughout the
26-week SHINE study [11] and the 64-week SPARK
study [13]. IND/GLY also significantly improved TDI
total scores compared with tiotropium [11, 12]. IND/
GLY demonstrated a favorable safety and tolerability
profile versus placebo in patients with moderate-to-
severe COPD over the 52-week ENLIGHTEN study
conducted in various countries, including Korea [14].
To add to this existing evidence presenting the ef-
ficacy of IND/GLY compared with tiotropium, this
randomized, multicenter, open-label, phase IV study
intends to demonstrate the efficacy of the switch to
IND/GLY from maintenance tiotropium therapy in
symptomatic patients with mild-to-moderate COPD.
This phase IV study design would directly switch the
patients receiving tiotropium to IND/GLY without
any washout period and thus differs from the design
of phase III clinical studies, in which, a switch to
the new therapy requires a washout period. This
moves the comparison of IND/GLY to the standard-
of-care tiotropium closer to real-life clinical practice.
GOLD strategy categorizes patients with COPD under
either A, B, C, or D category based on disease severity,
health status, and risk of exacerbations; however, few clin-
ical trials utilize these parameters for selection of
appropriate patients. Furthermore, although the combin-
ation of a LABA and a LAMA is recommended for treat-
ment of GOLD group B patients, a significant number of
such patients continue to experience symptoms and
breathlessness. The key feature of this study is to
emphasize enrollment of only GOLD group B patients
and to specifically assess the efficacy of IND/GLY in this
subset of the patients. Going beyond, this study would
allow demonstrating clear evidence on the benefits of
IND/GLY over tiotropium monotherapy in these patients.
In our opinion, the open-label design would not have any
effect on the outcomes because the primary measure in-
volves assessment of trough FEV1, which is inherent to the
treatment and not influenced by the investigator and par-
ticipant perception. Further, this open-label design also en-
ables to assess patient preference and satisfaction in
patients receiving IND/GLY, which is one of the
exploratory objectives of the study. This study is well de-
signed to demonstrate the use of LABA/LAMA combin-
ation and sufficiently powered to confirm the superiority of
IND/GLY over tiotropium in COPD patients with mild-to-
moderate airflow limitation. This study plans to answer the
question whether the use of a LABA/LAMA combination
would be preferable over continuing long-acting broncho-
dilator monotherapy in symptomatic COPD patients.
Trial status
The first patient’s first visit for the study took place in
January 2016 and the recruitment is expected to con-
clude by the end of 2017
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